Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
COGNITION THERAPEUTICS INC (CGTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/24/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Exhibit 99.1"
08/08/2023 8-K Quarterly results
Docs: "Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update"
06/12/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/04/2023 8-K Quarterly results
05/01/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Employment Agreement, by and between Cognition Therapeutics, Inc. and John Doyle"
04/19/2023 8-K Quarterly results
03/28/2023 8-K Quarterly results
03/23/2023 8-K Quarterly results
Docs: "Cognition Therapeutics Reports Year End 2022 Financial Results and Provides Business Update"
03/15/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Cognition Therapeutics Announces Development Plans for Oral CT1812 in Geographic Atrophy Secondary to Dry AMD , March 15, 2023 — Cognition Therapeutics, Inc. announced that its Investigational New Drug application for investigation of CT1812 for geographic atrophy secondary to dry age-related macular degeneration has been cleared by the U.S. Food and Drug Administration . Cognition plans to initiate the Phase 2 MAGNIFY trial of its oral drug candidate, CT1812 in 2023 in individuals with dry AMD who have measurable GA. “We enjoyed a collaborative dialogue with the ophthalmology division of the FDA during our pre-IND meeting and are excited to assess the potential of CT1812 to impact GA and slow the decline in visual acuity in people with dry AMD,” said Anthony Caggiano, M.D., Ph.D. , Cognit..."
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
03/10/2023 8-K Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Financial Statements and Exhibits ...
Docs: "292 Arch Street Suit",
"WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Investor, and the Investor wishes to buy from the Company, up to Thirty-Five Million Dollars of the Company’ s common stock, $0.001 par value per share . The shares of Common Stock to be purchased hereunder are referred to herein as the " Purchase Shares ." NOW THEREFORE, in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and the Investor hereby agree as follows: 1. CERTAIN DEFINITIONS. For purposes of this Agreement, the following terms shall have the following meanings:            &...",
"REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT , dated as of March 10, 2023, is entered into by and between COGNITION THERAPEUTICS, INC., a Delaware corporation , and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company . Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement by and between the parties hereto, dated as of the date hereof . WHEREAS: A.           Upon the terms and subject to the conditions of the Purchase Agreement, the Company has agreed to issue to the Investor, and the Investor has agreed to purchase, up to Thirty-Five Million Dollars of the Company's common stock, par value $0.001 per share , pursua..."
02/22/2023 8-K Quarterly results
02/13/2023 8-K Quarterly results
11/16/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Exhibit 99.1"
08/29/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Developing disease- modifying medicines for degenerative disorders August 2022"
08/09/2022 8-K Quarterly results
07/27/2022 8-K Quarterly results
06/16/2022 8-K Quarterly results
06/13/2022 8-K Quarterly results
05/11/2022 8-K Quarterly results
03/30/2022 8-K Quarterly results
Docs: "Cognition Therapeutics Reports Year End 2021 Financial Results and Provides Business Update"
03/15/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "EXPERIMENTAL THERAPEUTIC CT1812 DEMONSTRATES TARGET ENGAGEMENT IN A PHASE 1b CLINICAL TRIAL TO MEASURE DISPLACEMENT OF Aβ OLIGOMERS INTO CSF NJ Izzo PhD1, KM LaBarbera BS1, CM Yuede PhD2, L Waybright BS1, R Yurko MS1, YI Sheline MD3, HM Edwards BS2, WD Gardiner BS2, K Blennow MD4, H Zetterberg MD4, AB Hanson MD5, CS Davis PhD1, RJ Guttendorf PhD6, LS Schneider MD7, S DeKosky MD8, AO Caggiano MD1, M Grundman MD, SM9. Catalano PhD1, JR Cirrito PhD2, ME Hamby PhD1 1.Cognition Therapeutics, Inc, Pittsburgh, PA, USA, 2.Washington University, St Louis, USA, 3.University of Pennsylvania, Philadelphia, USA, 4. University of Gothenburg, Mölndal, Sweden, 5.Karolinska University Hospital, Stockholm, Sweden, 6.Aclairo, Vienna, USA, 7.Keck School of Medicine of USC, Los Angeles, USA, 8.Unive...",
"PROTEOMIC ANALYSIS OF CSF IN A PHASE 2 CLINICAL TRIAL FOR AD TO IDENTIFY PHARMACODYNAMIC BIOMARKERS OF THE S2R MODULATOR CT1812 N. Seyfried1 , L. Waybright2 , D. Duong1 , E. Malagise2 , K. Pandey3 , C. Williams2 , E. Dammer1 , L. Ping4 , K. Blennow5 , H. Zetterberg6 , J. Lah4 , A. Levey7 , L. Ricciardi2 , A.O. Caggiano2 , Mary E Hamby2 Affiliations: 1Emory University School of Medicine, Biochemistry, Atlanta, GA, United States of America, 2Cognition Therapeutics, Research, Pittsburgh, PA, United States of America, 3Emtherapro Inc, Systems Biology, Atlanta, GA, United States of America, 4Emory School of Medicine, Neurology, Atlanta, GA, United States of America, 5 Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Department of Psychiatry and Neuroc..."
01/10/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "OXIDATIVE STRESS PROTEIN AGGREGATES INFLAMMATION NUCLEUS ENDOPLASMIC RETICULUM VESICLE"
11/18/2021 8-K Quarterly results
Docs: "Cognition Therapeutics Reports Third Quarter Financial Results and Company Highlights"
11/12/2021 8-K Regulation FD Disclosure
11/03/2021 8-K Quarterly results
10/14/2021 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "Third Amended and Restated Certificate of Incorporation of Cognition Therapeutics, Inc",
"Amended and Restated Bylaws of Cognition Therapeutics, Inc"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy